Genflow Biosciences: AGM and partnership strategy - ICYMI Proactive uses images sourced from Shutterstock Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive about the company’s latest RNS regarding its upcoming AGM and the strategic rationale behind authorising the potential issuance of shares ahead of clinical partnership discussions. Leire addressed potential shareholder concerns, acknowledging that announcements involving share issuance can sometimes be int ...

Core Viewpoint - The article discusses a securities fraud class action lawsuit against uniQure N.V. due to a significant delay in FDA approval for its drug candidate AMT-130, which led to a 49% decline in the company's stock price [1]. Summary by Relevant Sections Lawsuit Details - Investors who purchased shares of uniQure between September 24, 2025, and October 31, 2025, have until April 13, 2026, to file lead plaintiff applications in the class action lawsuit [1]. - The lawsuit alleges that uniQure and its executives failed to disclose material information, violating federal securities laws [1]. FDA Approval and Stock Impact - During the class period, uniQure indicated a high likelihood of receiving accelerated FDA approval for AMT-130 following a planned Biologics License Application (BLA) submission in Q1 2026 [1]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from Phase I/II studies were adequate for BLA submission, resulting in a stock price drop of $33.40, or over 49%, from $67.69 to $34.29 per share [1].

Core Viewpoint - BioRestorative Therapies, Inc. has successfully closed a public offering of 14,285,715 shares of common stock and warrants, raising approximately $5.0 million to fund clinical trials and development initiatives [1][3]. Group 1: Offering Details - The public offering price was set at $0.35 per share, with warrants having the same exercise price and an expiration of five years from issuance [1]. - Rodman & Renshaw LLC served as the exclusive placement agent for the offering [2]. - The offering was registered with the SEC, and a final prospectus has been filed [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, development of a commercial biocosmeceuticals platform, and general corporate purposes [3]. Group 3: Company Overview - BioRestorative focuses on regenerative medicine, particularly stem cell-based therapies, with key programs targeting disc/spine diseases and metabolic disorders [6]. - The lead therapy candidate, BRTX-100, is designed for non-surgical treatment of lumbosacral disc disorders and is currently in Phase 2 clinical trials [6]. - The ThermoStem Program aims to develop therapies for obesity and metabolic disorders using brown adipose-derived stem cells [7]. - The company also operates a BioCosmeceutical platform, offering products aimed at cosmetic improvements [8][9].

Company Overview - Lexeo Therapeutics is a cardiac genetic medicines company focused on utilizing AAV gene therapy to address genetic cardiovascular diseases with high unmet needs [2] - The company's most advanced program targets Friedreich's ataxia, showing significant impacts on both cardiac and neurologic aspects of the disease [2] Treatment Efficacy - The gene therapy has resulted in all patients with abnormal heart mass returning to the normal range, indicating a positive effect on cardiac pathology [2] - Improvement in neurologic disease symptoms has been observed, with effect sizes on neurologic scales comparable to those of commercially approved therapies [2] Future Developments - Lexeo Therapeutics plans to move its Friedreich's ataxia program into a registrational study within the year, aiming to establish a new standard of care for this high unmet need disease [3]

WASHINGTON, D.C. 20549 As filed with the Securities and Exchange Commission on February 13, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Amendment No. 1 THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-1630228 (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (I.R.S. Employer ...

Core Insights - MRNA has experienced a pullback to a low of $36.66, indicating a potential successful test of support near the rising 10-week moving average at $37.74, suggesting readiness for a bullish trend continuation [1] - The key resistance level is identified at $55.20, where multiple indicators converge, and breaking this level could lead to accelerated bullish momentum [2] - Long-term upside targets for MRNA include the 200-week moving average at $92.99, with an initial target potentially being the 38.2% Fibonacci retracement at $76.72 [3] Group 1 - MRNA fell to a low of $36.66 this week, indicating a successful test of support near the 10-week moving average at $37.74 [1] - The area around $55.20 is identified as a key resistance level, with several technical indicators reinforcing this [2] - The 200-week moving average at $92.99 is highlighted as a long-term upside target, with the potential for MRNA to reach the top side of the falling channel [3] Group 2 - The bullish reaction following the low suggests that the pullback may complete the first phase after a long-term breakout [1] - The confluence of indicators at $55.20 suggests that breaking this level could confirm a continuation breakout [2] - The analysis indicates that the 38.2% Fibonacci retracement at $76.72 may be reached before the 200-week moving average [3]

Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Moderna Is Losing Less Money Than Expected. The Stock Jumps After Earnings.By [Nate Wolf]ShareResize---ReprintsIn ...

Company Overview - Olema is focused on transforming the standard of care for patients with ER-positive, HER2-negative breast cancer, which represents a significant unmet medical need [2] - Breast cancer is the most common cancer diagnosis in women globally and the second leading cause of cancer death, with ER-positive, HER2-negative breast cancer accounting for 70% of cases [2] Lead Program - The lead program of Olema is palazestrant, a complete estrogen receptor antagonist, which serves as the backbone therapy for ER-positive HER2-negative breast cancer [3] - Endocrine therapy is administered in every line of treatment until chemotherapy is necessary, with the goal of delaying chemotherapy as long as possible [3] Clinical Trials - Palazestrant is currently in two Phase III trials: one as a monotherapy in the second and third-line setting, with results expected in the fall, and another in combination with ribociclib in the first-line setting [4]

Core Insights - Moderna reported fourth-quarter results that exceeded expectations, with shares rising more than 8% intra-day on Friday [1] - The company posted a quarterly loss of $2.11 per share, narrower than analyst estimates of a $2.62 loss, and revenue reached $678 million, down 30% year over year [1] - For full-year 2025, Moderna generated revenue of $1.9 billion, representing a 40% decline from 2024, with a net loss of $2.8 billion or $7.26 per share [2] Financial Performance - Fourth-quarter revenue was $678 million, modestly above the consensus forecast of $662.84 million [1] - Full-year 2025 revenue was $1.9 billion, a 40% decline from 2024 [2] - Cash and investments totaled $8.1 billion at year-end 2025, down from $9.5 billion at the end of 2024 [2] Future Outlook - Moderna reaffirmed its goal of achieving up to 10% revenue growth in 2026, with approximately half expected from U.S. markets and half from international markets [3] - The company expects research and development expenses of approximately $3.0 billion and selling, general, and administrative expenses of about $1.0 billion for 2026 [4] - Year-end cash and investments for 2026 are projected to range between $5.5 billion and $6.0 billion [4] Pipeline Developments - Moderna reported full enrollment in its Phase 3 Norovirus trial, with data anticipated in 2026 [4] - The company also achieved full enrollment in its Phase 2 intismeran autogene study for muscle invasive bladder cancer [4] - The influenza vaccine filing has been accepted for regulatory review in the European Union, Canada, and Australia, but received a Refusal-to-File letter from the U.S. FDA [3]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]